Comparison of isoniazid monoresistant tuberculosis with drug-susceptible tuberculosis and multidrug-resistant tuberculosis.

L Fox, M R Kramer, I Haim, R Priess, A Metvachuk, D Shitrit
Author Information
  1. L Fox: Pulmonary Institute, Rabin Medical Center, Beilinson Campus, Petah Tikva, Israel.

Abstract

Limited data exist about the clinical characteristics of Mycobacterium tuberculosis (TB) isolates with resistance to isoniazid (IZN). We describe the demographic and clinical characteristics and risk factor information for persons with IZN monoresistant (resistant to isoniazid) TB compared with drug-susceptible TB and multidrug-resistant (MDR) TB. From 2002 to 2009, 590 cases of TB were diagnosed. Of these, 44 (7.5%) developed MDR-TB and 38 (6.4%) had IZN monoresistant TB. Among the IZN monoresistant TB patients, more common demographic characteristics were former resident of the Soviet Union immigrant, smoker, and previous history of TB (p = 0.005, 0.025, and 0.005, respectively), while HIV, weight loss, and hemoptysis were less common (p = 0.005 for all parameters). The mean length of treatment was 24 ± 4 months for MDR-TB, 10 ± 3 months for IZN monoresistant TB cases, and 8 ± 2 months for all other TB cases. The directly observed therapy (DOT) rate was similar in all three groups. However, treatment failure, completion of TB treatment, and mortality were all similar in drug-susceptible TB and higher in MDR-TB. In multivariate analysis, only a history of previous TB (odds ratio [OR] 1.4; 95% confidence interval [CI]: 1.2-1.6) was significantly associated with IZN monoresistant TB. IZN monoresistant TB has distinct characteristics. However, the length of treatment and outcome are similar to drug-susceptible TB cases.

References

  1. Arch Intern Med. 2008 Oct 13;168(18):1984-92 [PMID: 18852399]
  2. Am J Respir Crit Care Med. 2006 Apr 15;173(8):927-31 [PMID: 16424442]
  3. Arch Pharm (Weinheim). 2002;335(11-12):511-25 [PMID: 12596216]
  4. MMWR Recomm Rep. 2006 Jul 7;55(RR-9):1-44 [PMID: 16826161]
  5. Int J Tuberc Lung Dis. 2003 Oct;7(10):973-9 [PMID: 14552568]
  6. MMWR Recomm Rep. 1992 Jun 19;41(RR-11):5-48 [PMID: 1640920]
  7. JAMA. 1997 Sep 10;278(10):833-7 [PMID: 9293991]
  8. Clin Infect Dis. 2009 Jan 15;48(2):179-85 [PMID: 19086909]
  9. Chest. 2001 Jun;119(6):1730-6 [PMID: 11399698]

MeSH Term

Adult
Aged
Antitubercular Agents
Drug Resistance, Bacterial
Drug Therapy
Emigrants and Immigrants
Female
HIV Infections
Humans
Isoniazid
Israel
Male
Middle Aged
Mycobacterium tuberculosis
Risk Factors
Smoking
Time Factors
Treatment Outcome
Tuberculosis

Chemicals

Antitubercular Agents
Isoniazid

Word Cloud

Created with Highcharts 10.0.0TBIZNmonoresistantcharacteristicstuberculosisdrug-susceptiblecases0treatmentisoniazidMDR-TB005±monthssimilarclinicaldemographicmultidrug-resistant6commonprevioushistoryp=length4However1LimiteddataexistMycobacteriumisolatesresistancedescriberiskfactorinformationpersonsresistantcomparedMDR20022009590diagnosed4475%developed384%AmongpatientsformerresidentSovietUnionimmigrantsmoker025respectivelyHIVweightlosshemoptysislessparametersmean2410382directlyobservedtherapyDOTratethreegroupsfailurecompletionmortalityhighermultivariateanalysisoddsratio[OR]95%confidenceinterval[CI]:2-1significantlyassociateddistinctoutcomeComparison

Similar Articles

Cited By